Topics

Pharmaxis Ltd Company Profile

08:19 EST 14th November 2019 | BioPortfolio

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes: Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), ASM8 for asthma, PXS25 for idiopathic pulmonary fibrosis and a new oxidase inhibitor for lung disease. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.


News Articles [5 Associated News Articles listed on BioPortfolio]

EffRx to sell Pharmaxis' cystic fibrosis drug in Switzerland

Pharmaxis Ltd. licensed EffRx Pharmaceuticals SA exclusive rights to commercialize its cystic fibrosis drug Bronchitol (mannitol) in Switzerland.

EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol® in Switzerland

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has entered into an exclusive lic...

Bronchitol Gets Narrow Approval Vote From Advisory Cmte., Leaving US FDA Host Of Issues To Consider

Pulmonary-Allergy Drugs Advisory Committee votes 9-7 that the benefits of Pharmaxis' cystic fibrosis drug outweigh its risks, leaving the FDA...  &#

Global Cystic Fibrosis Drugs Market Research Report 20122024 [Published by HeyReport] Prices from USD $2210

SummaryThe global Cystic Fibrosis Drugs market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product ...

Global Cystic Fibrosis Drugs Market Research Report 20122024 [Report Updated: 22052019] Prices from USD $2210

SummaryThe global Cystic Fibrosis Drugs market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Pharmaxis Ltd

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory diso...

Pharmaxis

Pharmaxis Ltd is a specialist pharmaceutical company established to research, development and bring to market human therapeutic products to treat chronic respiratory and autoimmune diseases. Founded ...

Pharmaxis Ltd.

Pharmaxis, Inc.

More Information about "Pharmaxis Ltd" on BioPortfolio

We have published hundreds of Pharmaxis Ltd news stories on BioPortfolio along with dozens of Pharmaxis Ltd Clinical Trials and PubMed Articles about Pharmaxis Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmaxis Ltd Companies in our database. You can also find out about relevant Pharmaxis Ltd Drugs and Medications on this site too.

Quick Search

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...


Corporate Database Quicklinks



Searches Linking to this Company Record